Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $470 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.